New products
ASCO26: Data highlights test benefit in breast cancer treatment planning and earlier detection
Veracyte presented clinical data on its Prosigna genomic assay for breast cancer treatment planning at ASCO 2026, alongside findings from GRAIL's multi-cancer early detection test. The data highlighted the assays' utility in guiding therapy selection and enabling earlier cancer identification, supporting their role in precision oncology and screening workflows.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network